Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan ® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be ...

The global trastuzumab biosimilars market is expected to grow from $2.08 billion in 2021 to $2.64 billion in 2022 at a compound annual growth rate (CAGR) of 27.1%. The Russia-Ukraine war disrupted ...

The global market for Xolair, meanwhile, reached $3.63 billion in 2023, with Canada accounting for $138 million, according to Celltrion.

Celltrion remains the sole trastuzumab provider for the Brazilian government, with its Herzuma accounting for more than 50 percent of the market annually.

On September 13, 2024, Celltrion announced that its Brazilian subsidiary won the Federal Government of Brazil’s bid to supply HERZUMA (trastuzumab-pkrb) for the fifth consecutive year, with ...

Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a ...

Trastuzumab, a recombinant monoclonal antibody, acts against HER2 receptors. Design: In this international randomized trial, women who had undergone surgical excision of a HER2-positive, early ...

The company won the bid to supply a trastuzumab biosimilar to the Brazilian Federal Government for the fifth consecutive year. Under the contract, Celltrion will provide 660,000 vials of Herzuma ...